Please write to us on WhatsApp before ordering. Crypto payments only. Buyers are responsible for customs clearance, duties, import restrictions, and local regulations.
Paclitax NAB Injection 100mg: Complete Product Information for Buyers
Paclitax NAB Injection 100mg is a prescription anticancer medicine containing paclitaxel in a nanoparticle albumin-bound formulation, commonly called nab-paclitaxel.
According to the manufacturer’s professional product information, Paclitax NAB is supplied as 100 mg of nanoparticle albumin-bound paclitaxel in a single-use glass vial. It is a cytotoxic injectable medicine that must be prescribed by a qualified oncologist and administered intravenously in a hospital, oncology clinic, or other facility equipped to manage chemotherapy.
The “100 mg” description refers to the amount of paclitaxel contained in one vial. It does not mean that every patient receives a fixed 100 mg dose.
The actual treatment dose, schedule, number of vials, and combination medicines depend on the cancer type, body-surface area, blood counts, liver function, previous treatment, and individual tolerance.
This guide explains the formulation, approved uses, administration, safety warnings, storage requirements, and verification steps that patients, caregivers, pharmacists, clinics, hospitals, and licensed pharmaceutical buyers should understand.
Important: Paclitax NAB Injection is not suitable for self-medication or self-administration. The locally approved prescribing information and the treating oncologist’s instructions always take priority over general online information.
Paclitax NAB Injection 100mg: Complete Product Information for Buyers
Powder or lyophilized material for injectable suspension
Route of administration
Intravenous infusion
Medicine category
Cytotoxic taxane chemotherapy
Administration setting
Hospital or specialist oncology facility
Prescription status
Prescription-only medicine
Self-administration
Not appropriate
The exact packaging, diluent presentation, registration number, approved indications, and storage instructions can vary by country and commercial pack. Buyers should verify the information printed on the actual carton and vial rather than relying solely on online descriptions.
What Does “NAB” Mean?
“NAB” refers to nanoparticle albumin-bound paclitaxel.
In this formulation, paclitaxel is associated with human albumin in very small particles. Albumin is a naturally occurring protein found in human blood.
This formulation is different from conventional solvent-based paclitaxel injection. Nab-paclitaxel and conventional paclitaxel may contain the same active anticancer substance, but they differ in formulation, preparation, dosing schedules, infusion requirements, and safety considerations.
Paclitax NAB Is Not Interchangeable with Conventional Paclitaxel
This is one of the most important safety points for buyers and healthcare teams.
Regulatory prescribing information for albumin-bound paclitaxel specifically warns that it should not be substituted for or with other paclitaxel formulations. Conventional paclitaxel injection and nab-paclitaxel are not automatically interchangeable on a milligram-for-milligram basis.
Before accepting or dispensing a product, verify whether the prescription requires:
Conventional paclitaxel injection
Paclitaxel protein-bound particles
Albumin-bound paclitaxel
Nab-paclitaxel
A particular approved brand or generic formulation
A package labeled only “paclitaxel” should not be assumed to match a prescription for nab-paclitaxel.
How Does Nab-Paclitaxel Work?
Paclitaxel belongs to a class of chemotherapy medicines called taxanes.
Cancer cells must reorganize structures called microtubules in order to divide. Paclitaxel binds to microtubules and stabilizes them, preventing the normal changes required for cell division.
This disruption can stop susceptible cancer cells from multiplying and may eventually lead to cell death.
Because chemotherapy can also affect normal rapidly dividing cells, treatment may cause effects involving:
Bone marrow
Hair follicles
Gastrointestinal tissues
Peripheral nerves
Reproductive cells
This is why patients require regular monitoring throughout treatment.
The approved uses of nab-paclitaxel vary by product and country.
The professional monograph for Paclitax NAB describes its use for breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior treatment should generally have included an anthracycline unless it was clinically unsuitable.
Other internationally authorized albumin-bound paclitaxel products have approved uses that may include:
Metastatic breast cancer
Locally advanced or metastatic non-small cell lung cancer in combination with carboplatin
Metastatic pancreatic adenocarcinoma in combination with gemcitabine
These broader indications appear in current regulatory labeling for certain nab-paclitaxel products, but they must not automatically be applied to every brand or every country.
In March 2026, the US FDA also approved relacorilant in combination with nab-paclitaxel for certain patients with platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer. That approval concerns a specific combination and patient population; it does not independently expand every Paclitax NAB product label worldwide.
Why Buyers Must Check the Local Label
A medicine may have:
Different indications in different countries
Different approved combination therapies
Different dosage instructions
Different package inserts
Different regulatory status
Different import or dispensing restrictions
The correct reference is the prescribing information approved by the medicine regulator in the destination country.
Does 100mg Mean the Patient Receives 100mg?
No.
The 100 mg refers to the strength of one vial. Oncology doses are often calculated in milligrams per square meter of body-surface area, written as mg/m².
The final dose may require:
One vial
More than one vial
Part of the reconstituted contents
Dose reduction
Treatment delay
Treatment interruption
The treating oncology team calculates the required dose.
For example, the Paclitax NAB manufacturer monograph describes a breast-cancer regimen based on 260 mg/m² administered intravenously over approximately 30 minutes every three weeks. Other albumin-bound paclitaxel labels use different schedules for lung or pancreatic cancer.
Patients and buyers should never calculate the treatment dose from the vial strength alone.
How Is Paclitax NAB Injection Administered?
Paclitax NAB is administered as an intravenous infusion by trained healthcare professionals.
It must first be prepared according to the product-specific instructions. Preparation and administration involve cytotoxic-drug precautions because accidental exposure may be harmful.
Healthcare personnel may need to:
Inspect the vial and packaging.
Confirm the prescribed formulation and strength.
Calculate the patient-specific dose.
Reconstitute the vial using the approved procedure.
Inspect the suspension for visible abnormalities.
Transfer the correct volume to the infusion container.
Administer it through an intravenous line.
Monitor the infusion site and the patient.
Dispose of unused material as hazardous pharmaceutical waste.
The manufacturer states that Paclitax NAB should only be administered under the supervision of a qualified oncologist in a unit experienced in cytotoxic medicines. Gloves and appropriate handling precautions are recommended.
Does Paclitax NAB Require Premedication?
Routine premedication practices may differ from those used with conventional solvent-based paclitaxel.
The Paclitax NAB professional monograph states that routine premedication to prevent hypersensitivity reactions is not required under its labeled administration instructions. However, current regulatory labeling for other albumin-bound paclitaxel products advises clinicians to consider premedication in patients with a previous hypersensitivity reaction.
Premedication should therefore be determined by the treating oncology team, not by the patient or supplier.
Important Warnings and Precautions
Paclitax NAB is a potent chemotherapy medicine. Treatment requires medical supervision, blood testing, and assessment for serious adverse reactions.
Bone-Marrow Suppression
Nab-paclitaxel can reduce the production of blood cells.
This may cause:
Neutropenia
Leukopenia
Anemia
Thrombocytopenia
Increased infection risk
Increased bleeding risk
The medicine should not be administered when baseline neutrophil counts are below the threshold specified in the approved label. Frequent complete blood counts are required, and treatment may need to be delayed or reduced.
Peripheral Neuropathy
Peripheral neuropathy can cause:
Numbness
Tingling
Burning sensations
Pain
Reduced sensation
Weakness in the hands or feet
Neuropathy is dose- and schedule-dependent. Severe symptoms may require treatment interruption and a reduced dose after improvement.
Infection and Sepsis
Reduced white blood cell counts can make infections more serious.
Patients should urgently contact their medical team if they develop:
Fever
Chills
Persistent cough
Shortness of breath
Painful urination
Severe weakness
Confusion
Signs of an infected catheter or wound
Sepsis has been reported, particularly in some patients receiving albumin-bound paclitaxel with gemcitabine.
Hypersensitivity Reactions
Severe hypersensitivity reactions, including fatal reactions, have been reported with protein-bound paclitaxel.
Symptoms may include:
Difficulty breathing
Wheezing
Facial or throat swelling
Sudden rash
Severe flushing
Dizziness
Low blood pressure
Patients who experience a severe hypersensitivity reaction should not ordinarily be rechallenged with the product.
Liver Impairment
Paclitaxel exposure and toxicity can increase in patients with impaired liver function.
Liver-function tests should be reviewed before and during treatment. Some patients require a reduced starting dose, while the medicine may not be recommended in severe hepatic impairment or for particular indications.
Pneumonitis and Breathing Problems
Inflammation of the lungs, including potentially fatal pneumonitis, has been reported with protein-bound paclitaxel, particularly in some combination regimens.
New or worsening cough, shortness of breath, fever, chest discomfort, or low oxygen levels require prompt medical evaluation.
Pregnancy, Fertility and Breastfeeding
Paclitaxel can harm a developing fetus.
Patients who could become pregnant may require pregnancy testing and effective contraception. Male patients with partners who could become pregnant may also be advised to use contraception for a specified period after treatment.
Breastfeeding is not recommended during treatment and for the period stated in the locally approved prescribing information.
The manufacturer’s monograph identifies bone-marrow suppression, neuropathy, gastrointestinal effects, hair loss, musculoskeletal pain, fatigue, fever, and skin reactions among important reported toxicities.
Not every patient experiences every side effect. Patients should report new or worsening symptoms to their oncology team rather than stopping treatment independently.
What Monitoring Is Required?
Before and during therapy, the healthcare team may monitor:
Complete blood count
Absolute neutrophil count
Platelet count
Liver function
Kidney function where clinically relevant
Symptoms of neuropathy
Signs of infection
Breathing symptoms
Infusion-site reactions
Pregnancy status when applicable
Response to cancer treatment
The treatment may be delayed, reduced, or discontinued when laboratory results or toxicities make further administration unsafe.
Storage Requirements
The Paclitax NAB manufacturer monograph states that unopened vials should be stored in their original packaging below 25°C and protected according to the carton instructions.
For the product described in that monograph:
The unopened vial should remain in its original carton.
The medicine should be protected from inappropriate heat and bright light.
Reconstituted material should preferably be used immediately.
When necessary, the reconstituted vial may be refrigerated at 2°C to 8°C for the limited period specified in the insert.
Prepared infusion material must be used within the allowed in-use period.
Unused portions must be discarded.
Storage limits differ between manufacturers. For example, some current albumin-bound paclitaxel labels permit a longer refrigerated in-use period than the Paclitax NAB monograph. The product-specific carton and leaflet must therefore be followed exactly.
What Should Buyers Check Before Accepting the Product?
Because oncology medicines are high-risk products, verification should include more than checking the product name.
1. Confirm the Exact Formulation
The packaging should clearly identify:
Paclitaxel nanoparticle albumin-bound
Albumin-bound paclitaxel
Nab-paclitaxel
Do not accept conventional paclitaxel as an automatic substitute.
2. Verify the Strength
Confirm that both the carton and vial state:
100 mg
Check whether the pack contains a single-use vial and any accompanying diluent described by the manufacturer.
3. Match the Carton and Vial
Compare:
Product name
Strength
Manufacturer
Batch or lot number
Expiry date
Registration details
Barcode or serialization code
Any inconsistency should be investigated before the medicine is dispensed or used.
4. Inspect the Physical Condition
Do not accept a product with:
Broken vial
Cracked glass
Missing label
Damaged seal
Wet carton
Evidence of leakage
Altered expiry information
Unreadable batch number
Signs of unauthorized relabeling
Unexplained temperature exposure
5. Verify the Supplier
Prescription oncology medicines should be obtained only through authorized and traceable pharmaceutical channels.
The World Health Organization advises patients and healthcare systems to obtain medicines from trusted, licensed outlets because falsified products can look almost identical to genuine medicines. Cancer medicines are among the products that can be affected by falsification.
Institutional buyers should verify, where applicable:
Pharmacy or wholesale licence
Manufacturing or distribution authorization
Purchase invoice
Supplier identity and address
Product registration
Traceable batch information
Transport and storage records
Recall contact procedure
Wholesale distributors in regulated markets may also be required to follow Good Distribution Practice and obtain products only from appropriately authorized suppliers.
Illustrative Procurement Case
A hospital procurement team receives two quotations:
Quotation A: Paclitax NAB Injection 100mg
Quotation B: Paclitaxel Injection 100mg
Although both products contain paclitaxel and both display “100 mg,” they are not necessarily equivalent.
Before placing an order, the pharmacist should confirm:
Which formulation appears on the oncologist’s prescription.
Whether albumin-bound paclitaxel is specifically required.
Whether the quoted product is authorized in the destination country.
Whether its approved indication matches the treatment protocol.
Whether the supplier is licensed.
Whether storage and transportation comply with the product label.
Whether the batch, expiry date, and manufacturer are traceable.
Selecting solely on price could create a serious medication error.
Frequently Asked Questions
Is Paclitax NAB Injection the Same as Abraxane?
Both are names associated with nanoparticle albumin-bound paclitaxel formulations, but they are not the same commercial product.
Abraxane is a reference brand in several markets. Paclitax NAB is a separate branded product. Regulatory approval, excipients, packaging, local indications, and prescribing information must be checked for the exact product supplied.
Is Paclitax NAB the Same as Ordinary Paclitaxel Injection?
No.
Both contain paclitaxel, but the formulations and administration instructions differ. They should not be substituted without explicit clinical and pharmacy authorization.
Can a Patient Inject Paclitax NAB at Home?
No.
It must be prepared and administered intravenously by trained healthcare professionals in an appropriate clinical setting.
Can the 100mg Vial Be Used as a Fixed Dose?
No.
The prescribed dose is calculated for the individual patient. The vial strength is not the same as the treatment dose.
Does Paclitax NAB Always Require Refrigerated Shipping?
The unopened Paclitax NAB product described by the manufacturer is stored below 25°C in its original carton, rather than routinely as a refrigerated unopened vial. However, the actual carton instructions, transport conditions, local climate, and product-specific label must be followed.
Can an Expired Vial Be Used?
No.
Expired, damaged, improperly stored, or unverifiable vials should not be administered.
Can Buyers Import It for Personal Use?
Rules differ between countries. Prescription anticancer medicines may require a prescription, import authorization, licensed consignee, customs documentation, or hospital involvement.
Buyers should confirm the destination country’s pharmaceutical import rules before arranging shipment. A successful shipment does not by itself establish that importation, dispensing, or use is lawful.
Final Buyer Checklist
Before accepting Paclitax NAB Injection 100mg, confirm:
The prescription specifies nab-paclitaxel
The product name is correct
The strength is 100 mg
The formulation is albumin-bound
The manufacturer is identifiable
The product is authorized for the intended market
The supplier is licensed and traceable
The carton and vial details match
The batch number is clear
The expiry date is valid
The seal and vial are intact
Storage conditions were maintained
The approved leaflet is available
A pharmacist has reviewed the product
Administration will occur in a qualified oncology facility
Conclusion
Paclitax NAB Injection 100mg is a nanoparticle albumin-bound paclitaxel chemotherapy product intended for specialist intravenous administration.
The 100 mg label refers to the vial strength, not a universal patient dose. Treatment must be individually prescribed and may require multiple vials, dose reductions, delays, or combination medicines.
The most important considerations for buyers are formulation accuracy, licensed sourcing, product authorization, batch traceability, correct storage, and professional oncology supervision.
Paclitax NAB must not be treated as interchangeable with conventional paclitaxel merely because the active ingredient and strength appear similar. Any uncertainty about the prescription, product label, storage history, or supplier should be resolved by a qualified pharmacist or oncology professional before the medicine is accepted or administered.
